The Cautionary Tale

The attribution gap: why 'no deaths reported' isn't a safety record

By Tan Lines·Published September 14, 2026

Underneath nearly every defense of Melanotan II sits the same load-bearing sentence: millions of people have used it for twenty-odd years, and no deaths have ever been reported. It is offered as epidemiology. It is the opposite of epidemiology — it is a statement about the absence of an epidemiological system, dressed as a finding.

The claim contains two numbers. How many people used it, and how many of them died. Follow either one backward and it dissolves. This article follows both.

The denominator no one counted

The nearest thing the medical literature has to a prevalence figure is an editorial the BMJ published in February 2009. Its authors — led by Michael Evans-Brown, then a researcher studying performance-enhancing drugs at Liverpool John Moores University — had come to melanotan the way public-health people come to everything nobody tracks: through the sharps bin. Staff at needle-and-syringe programmes in England and Wales had started reporting clients who injected the peptide for tanning and for its sexual effects, and were asking what anyone knew about it.

What anyone knew was this, and the editorial says it in one sentence: the prevalence of the use of these drugs is unknown. Not estimated. Not “thought to be large.” Unknown — the confession of a surveillance system being asked about a product it was never built to see.

Nothing has made that number countable since. An unlicensed product generates no prescriptions, no dispensing records, no sales data, no tax trail. The market that grew up to supply it was deliberately engineered to leave no paper — the payment camouflage and research-chemical word games are documented in how it’s sold now. A market with no records cannot have a user count. So the “millions” figure has floated for two decades, quoted by clinics, forums, and sellers, with no source and no method. A number that survives twenty years without ever being counted is not a finding; it is a mood.

The numerator no one was obliged to count

For a licensed medicine, harm has plumbing. The manufacturer must report adverse events; the prescriber can file a Yellow Card or a MedWatch report; pharmacovigilance is a funded department, not a favor. None of that plumbing exists for a drug that is not a drug. Reporting to regulators is technically open — anyone can submit a Yellow Card about anything — but the report needs a product to name, and you can’t know what’s in the vial. It needs a clinician to suspect the right thing, and the side effects of melanocortin flooding are things most emergency staff have never seen filed under a drug name. The only harvest from twenty years of unregulated use is what has been dramatic enough to force its way into print, one case at a time:

• A 20-year-old woman who seized after injecting it, reported in the Annals of Internal Medicine in May 2013 — the first published association of melanotan with posterior reversible encephalopathy syndrome.
• A man in Glasgow with an erection that would not resolve, reported in BMJ Case Reports in February 2019, under the unbeatable title “a hard-earned tan.”
• The overdose case that reached the emergency department with rhabdomyolysis and kidney injury, already on the side-effect ledger.

Those are leaks through the floor of the counting system, not measurements of it. And the system’s actual output — the complete Australian adverse-event file the regulator could point to — is small enough to hold in one sentence. According to The Record, the entire pool that moved the TGA to reclassify Melanotan II alongside heroin in February 2026 was 89 reports, over four years (2022–2025), including two melanoma diagnoses within eighteen months of use.

Sit with that number, because it cuts in both directions. If the user base is really “millions,” then 89 reports in four years means the reporting pipe catches almost nothing — and “no deaths reported” measures the pipe, not the harm. If the 89 reports are close to the truth, then the denominator was never millions and the safety argument has no premise either. You cannot tell which world you are in, because nobody has the denominator. The claim’s two numbers were never going to be reconcilable.

The inquest: what the system does when harm is undeniable

In September 2012, a 26-year-old woman named Jenna Wilson-Vickers was found collapsed in a stand-up tanning cabinet at a salon in Bolton. The coroner’s court heard that she had been injecting Melanotan II into her stomach for weeks — a vial bought from a UK tanning website — and that the morning she died was the third 12-minute session she had taken in three days. She was dead at the scene.

The inquest the following year is the single most rigorous harm assessment the gray market has ever generated: a court, a pathologist, an examination. And the pathologist’s evidence, quoted in full by the BBC, is the sentence this whole story turns on:

“It remains that there is insufficient information in respect of Melanotan II to allow any realistic assessment of its significance in the death of Jenna. The possibility of adverse reaction to Melanotan can’t be excluded, but there is no evidence to suggest it does. I can’t link it to the medical cause of death.”

The jury found the death was heart failure related to obesity; it never reached the peptide. The seller’s site closed after a police caution.

Read what that verdict actually is. Not an acquittal, and not a conviction — the words foreclose both. It is the legal system stating that after twenty-plus years of supposedly massive use, there is insufficient information to assess a suspect compound’s role in the one harm no one can miss: a young body on a salon floor, examined by a court. The forums’ “no deaths have ever been attributed to it” is an echo of this machinery. Deaths can’t be attributed because the attribution capacity is zero — and the same zero is what the seller counts as a clean record.

Survivorship theatre

The evidence base the claim leans on, stripped down, is the forum archive. But a forum is a sample of the people still well enough, and still here, to post. The user who develops a mole problem worth biopsying has mostly left the thread; the one whose skin or stomach reacted badly to a spray has no reason to announce which product he bought. Chartered Trading Standards Institute officers told The Guardian in May 2025 of severe allergic reactions and hospitalisations among nasal-spray users — one of them a King’s Lynn woman who described feeling, after a single spring-2023 use, like she was “drowning inside her own body.” Her account surfaced only because she volunteered it to a newspaper. The lead officer’s summary is the sentence that should be welded to the “millions” claim: “no one, including influencers, can truly know the risks of using these quasi-medical potions.”

And when a forum regular is harmed, the harm hides in the stack. The peptide travels through exactly the gym populations that run anabolic steroids and whatever else is loose — the peer-reviewed steroid-epidemiology literature lists melanotan among the co-used compounds. When a body with that mixture fails, nobody’s paperwork names the tanning drug. The side-effect ledger calls case reports “signals, not base rates.” The signals are the base rate of a system that was never measuring.

What twenty years of data would look like

For contrast, the same receptor family, the same Arizona-derived line of chemistry, the front door. Bremelanotide — the libido drug that the accident inside the peptide gave the world — was approved by the FDA on 21 June 2019 on trials that enrolled 1,247 premenopausal women in two identical 24-week randomized studies, with a further 684 in a year-long extension. The label can say, to the percentage point, that focal hyperpigmentation runs at 1%, and can describe a blood-pressure effect transient enough to be measured to the hour.

That is a small number of people. It is also every one of those people counted — dosed, watched, reported. That is what twenty years of medicine looks like. The gray market’s twenty years look like 89 reports, a handful of case studies, and a coroner’s “insufficient information.” The comparison is the thesis of this whole publication in miniature: volume and evidence are different things — and the reason no one has ever enumerated the actual tanning peptide is the funding problem who would pay for the trial already documents.

Try the claim next time it needs you

The next time the defense rolls out — millions of users, twenty years, no deaths — you don’t need a horror story to answer it. You need three questions, and the sources above to back them. Which millions, and who counted? Twenty years of what data, kept by whom? No deaths reported by what system?

The honest middle, as always here, is smaller than either side wants: nobody knows what this drug has cost, and there has never been a machine capable of knowing. That isn’t reassurance and it isn’t alarm. It is the absence of evidence, wearing the costume of evidence — and every year of “no deaths reported” adds nothing to count. This publication will keep counting what can be counted: the 89, the case reports, the label percentages, the jury words. Harms plain; uncertainty not smoothed.